Keith Speights

Keith Speights

TMFFishBiz

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

Vaccine bottles

Why Novavax Shares Vaulted Higher Today

It's a little complicated.


Beaker with money

What's Behind Alexion's Impressive Q3 Results

The biotech delivered strong top- and bottom-line growth and boosted its full-year outlook.


Scientist with coronavirus

Why Investors Loved Moderna's Q3 Results

The biotech has plenty of cash and could be on the verge of its biggest success ever.


Q3 on a sticky note

Why Penumbra Stock Is Popping Today

The healthcare company posted better-than-expected Q3 results.


Scientist holding vaccine bottle and syringe

Why BioNTech Stock Is Jumping Today

The overall stock market surge appears to be inspiring investors to leap back into the German biotech stock.

Magnifying glass over remdesivir

Why the Luster of Gilead's Strong Q3 Results Isn't as Bright as It Seems

Sales soared for the biotech's new COVID-19 drug, but Gilead faces some challenges in other areas.


Boy receiving a vaccine

Here's the Clear Leader in Developing a Coronavirus Vaccine for Kids

So far, only one late-stage study evaluating a COVID-19 vaccine candidate includes children.


'I voted' stickers on top of money

These 3 Stocks Are Buys No Matter What Happens in the 2020 Election

Here are three top stocks that offer win-win propositions.


Scientist in lab with arms crossed

Thank Otezla for Amgen's Q3 Revenue and Earnings Beats

Without the purchase of the blockbuster autoimmune disease drug, Amgen's latest results wouldn't have looked nearly as good.


COVID vaccine with dollar sign

Why Coronavirus Vaccine Stocks Moderna, Novavax, and Inovio Are Sinking Today

The overall stock market sell-off is pulling all three biotech stocks down.

About to give shot to patient

AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race

Some things have changed, but others haven't.


Dexcom G6_full family (2)

How DexCom Trounced Wall Street Estimates in Q3

The diabetes care technology provider also again raised its full-year guidance.


Dry eyes diagnosis form

Why Kala Pharmaceuticals Stock Sank Today

Good news from the FDA translated to bad news for Kala's share price.


scientist in lab

How Pfizer Missed an Opportunity With Its Q3 Results

The big drugmaker posted mixed third-quarter numbers. However, several key catalysts should be right around the corner.


Physician holding a vaccine shot

Why Novavax Stock Is Moving Higher Today

The biotech gave an encouraging update about its late-stage coronavirus vaccine program.

November 2020

5 Top Stocks for November

These stocks should provide you with plenty to be thankful for over the long run.


Finger pointing to chart sloping upward

Why Scholar Rock Stock Is Skyrocketing Today

Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.


Small bottles with ice on top of them

Could Some Coronavirus Vaccines Be Left Out in the Cold?

Some coronavirus vaccines must be stored at extremely low temperatures. Could this limit their market potential?


Man looking at stock chart on iPad

Market Crash 2.0: Where to Invest $1,000

These three stocks should win if another market crash is at hand. And they should perform well if the bull market continues, too.


Three arrows hitting dollar sign on target

3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market

And they all offer attractive dividends, too.